Science Daily: Pharmacology News

JULY 10, 2025

Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.

Disease 276

Disease 276

BioPharma Drive: Drug Pricing

JULY 10, 2025

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

Treatment 252

Treatment Disease Drugs 252

Drugs.com

JULY 8, 2025

TUESDAY, July 8, 2025 — More Florida teens are roaming the streets packing heat, a new study says.Handgun carrying among Florida middle and high school students increased by 65% between 2002 and 2022, researchers reported July 7 in the journal P.

Research 219

Research 219

Collaborative Drug

JULY 10, 2025

CDD Vault Update (July 2025): Custom Axis Scaling, AUC Fold Change, Copy Reactions and Stoichiometry Tables, and Sample Tracking Improvements for the ELN

179

179

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Covalent Modifiers

JULY 9, 2025

Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew. Chem. Int. Ed. 2025 , e202508427. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule DNA Disease 130

Science Daily: Pharmacology News

JULY 12, 2025

Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.

Research 262

Research Regulations Therapies Disease 262

Drugs.com

JULY 8, 2025

TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says.Corticosteroids are commonly prescribed to alleviate cancer-related symptoms in patients w.

Treatment 264

Treatment Drugs 264

Collaborative Drug

JULY 8, 2025

BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.

Drugs 147

Drugs Pharmaceuticals 147

Chemical Biology and Drug Design

JULY 11, 2025

Aplysinopsin analog 12g displayed moderate antiproliferative activity upon breast and cervical cancer cells, and in Zebrafish-based model showed the lethality rate of embryos and larvae, sublethal effects and significant inhibition of larvae growth in a period higher than cytotoxicity assay. In silico ADME analysis indicated 12g with good orally bioavailable.

Drugs 100

Drugs Research 100

Science Daily: Pharmacology News

JULY 14, 2025

A new leap in lab automation is shaking up how scientists discover materials. By switching from slow, traditional methods to real-time, dynamic chemical experiments, researchers have created a self-driving lab that collects 10 times more data, drastically accelerating progress. This new system not only saves time and resources but also paves the way for faster breakthroughs in clean energy, electronics, and sustainability—bringing us closer to a future where lab discoveries happen in days, not y

Research 224

Research 224

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

BioPharma Drive: Drug Pricing

JULY 11, 2025

The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the agency during deramiocel’s review.

Therapies 259

Therapies FDA 259

Drugs.com

JULY 9, 2025

WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer.Unfortunately, that hope doesn’t extend to people without health insurance, a new study says.Immune checkpoint inh.

Treatment 217

Treatment 217

LifeSciVC

JULY 10, 2025

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are a first-time founder who has heard the phrase “This isn’t a good time to be raising for X,” where X is a platform, a preclinical play, a non-consensus story, I empathize! After you’ve spent years contemplating an idea, potentially investing some of your own money to generate early data, and carefully thinking through the pitch, it’s difficult to hear that an entire scope of companies is

Science 101

Science Clinical Trials Marketing Trials 101

Drug Target Review

JULY 10, 2025

Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in small molecule drug discovery. Medicinal chemists often describe ADMET optimisation as a frustrating ‘whack-a-mole’ problem: improve one property and another tends to deteriorate.

Metabolic Stability 72

Metabolic Stability Drugs Drug Development Small Molecule 72

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Science Daily: Pharmacology News

JULY 14, 2025

Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, the gel steadily releases levodopa and carbidopa for seven days, helping keep tremors and stiffness in check while easing side effects linked to fluctuating doses.

Research 222

Research 222

BioPharma Drive: Drug Pricing

JULY 9, 2025

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

Doctors 184

Doctors FDA Drugs 184

Drugs.com

JULY 10, 2025

THURSDAY, July 10, 2025 -- The U.S. Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as replies to drug and biological product applications submitted to the agency from 2020 to 2024.The.

FDA 208

FDA Drugs Production 208

Drug Patent Watch

JULY 9, 2025

"The Future of Pharma is in Flux: Can AI-Designed Medicines Be Owned? As the pharmaceutical industry grapples with the rise of generative AI, a new question is emerging: who owns the rights to medicines designed by machines? In a groundbreaking development, researchers have successfully used AI to design novel compounds with unprecedented efficacy.

Pharmaceuticals 78

Pharmaceuticals Drugs Marketing Research 78

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

addgene Blog

JULY 8, 2025

This post was written by Alfonso Timoneda, with significant contributions from Robert Hurt and Mohamed Soufi. So you’ve learned about the Modular Cloning (MoClo) system and what it can do for you, and you’ve chosen one of the MoClo kits available through Addgene that suits your experimental purposes. But what now? MoClo really simplifies vector construction by combining restriction and ligation steps together in the same tube at the same time, however, it can prove itself to be quite the mental

76

76

Science Daily: Pharmacology News

JULY 10, 2025

Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through neural highways and how certain genes either accelerate its toxic journey or shield brain regions from damage. Their extended Network Diffusion Model pinpoints four gene categories that govern vulnerability or resilience, reshaping our view of Alzheimer’s progression and spotlighting fresh therapeutic targets.

Government 211

Government 211

BioPharma Drive: Drug Pricing

JULY 8, 2025

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.

Treatment 193

Treatment 193

Drugs.com

JULY 11, 2025

FRIDAY, July 11, 2025 — A drug used to treat seizures, nerve pain and restless leg syndrome might be linked with increased risk of dementia, a new study says. Regular gabapentin use appeared to increase risk of dementia by 29% and mild.

Drugs 279

Drugs 279

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Target Review

JULY 11, 2025

Neurological diseases are among the most complex and least understood conditions in medicine. Despite the knowledge that certain genes increase the risk of contracting diseases like Alzheimer’s and Parkinson’s, it is still not fully understood how those diseases develop in the brain. But that is beginning to change. At the centre of this shift is 10x Genomics – a company building tools that enable researchers to study individual cells and their gene activity, both in isolation and in their origi

Molecular Biology 69

Molecular Biology Disease Therapies Bioinformatics 69

New Drug Approvals

JULY 9, 2025

Sunvozertinib CAS 2370013-12-8 DZD9008, 584.1 g/mol, C 29 H 35 ClFN 7 O 3 , A-1801, L1Q2K5JYO8 N -[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3 R )-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide FDA Zegfrovy, 7/2/2025 To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based c

FDA 62

FDA FDA Approval Clinical Trials Trials 62

Science Daily: Pharmacology News

JULY 12, 2025

A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats with cognitive decline, beyond the infamous amyloid and tau plaques long blamed for Alzheimer’s. These shape-shifting proteins don’t clump into visible plaques, making them harder to detect but potentially just as harmful. Scientists believe these “stealth” molecules could evade the brain’s cleanup systems and quietly impair memory and brain function.

Treatment 205

Treatment 205

BioPharma Drive: Drug Pricing

JULY 8, 2025

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

Trials 161

Trials Therapies 161

Drugs.com

JULY 11, 2025

FRIDAY, July 11, 2025 — Moderna’s COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.The move makes Moderna’s vacci.

Vaccine 283

Vaccine FDA Drugs 283

Drug Target Review

JULY 15, 2025

The next-generation sequencing (NGS) market is experiencing rapid growth, which is expected to continue for the foreseeable future. Research by Markets and Markets projects the market to grow from $12.13 billion in 2023 to about $23.55 billion by 2029, a compound annual growth rate (CAGR) of approximately 13.2 percent.​ 1 Emergen Research attributes this to the advantages of high-throughput sequencing technologies and declining sequencing costs​. 2 This trend reflects the increasing demand for g

RNA 59

RNA DNA Laboratories Science 59

New Drug Approvals

JULY 13, 2025

Rezatapopt, PC 14586 CAS 2636846-41-6 Molecular Weight 545.57 Synonyms PC14586 Formula C 28 H 31 F 4 N 5 O 2 CAS No. 2636846-41-6 4-[3-[4-[[(3 S ,4 R )-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy- N -methylbenzamide 4-[3-[4-[[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzamide Benzamide, 4-[[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroe

Pharmaceuticals 62

Pharmaceuticals Small Molecule Production Trials 62

Science Daily: Pharmacology News

JULY 13, 2025

For centuries, we’ve imagined Neanderthals as distant cousins — a separate species that vanished long ago. But thanks to AI-powered genetic research, scientists have revealed a far more entangled history. Modern humans and Neanderthals didn’t just cross paths; they repeatedly interbred, shared genes, and even merged populations over nearly 250,000 years.

DNA 279

DNA Research 279

BioPharma Drive: Drug Pricing

JULY 10, 2025

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving medicines that it later cleared.

FDA 170

FDA Drugs 170

Drugs.com

JULY 8, 2025

TUESDAY, July 8, 2025 — Three-quarters of stomach cancer cases could be prevented if doctors eradicate infection by a common type of bacteria, a new study says. The bacteria, Helicobacter pylori, is linked to 76% of future stomach cancer.

Doctors 262

Doctors 262